Literature DB >> 10159723

Blepharospasm and related facial movement disorders.

B C Patel1, R L Anderson.   

Abstract

The variable clinical features and the relatively good response of blepharospasm to botulinum-toxin type A are now well established. The etiology and pathophysiology of blepharospasm and related facial movement disorders are still poorly understood. Genetic and histopathologic studies over the last year have contributed to our understanding of this disease. The most significant progress has been made in the electromyographic studies of the the levator palpebrae and orbicularis oculi muscles. Subclassification based on the electromyographic abnormalities of these two muscles have begun to improve our understanding of the variable responses to botulinum-toxin type A. Further electromyographic studies may help identify the best sites of injection for optimal response and differentiate patients requiring limited or complete myectomy. The development of the limited myectomy has provided excellent functional and cosmetic results with quick recovery times in selected patients.

Entities:  

Mesh:

Year:  1995        PMID: 10159723     DOI: 10.1097/00055735-199510000-00014

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  3 in total

1.  Clinical features of patients with blepharospasm: a report of 240 patients.

Authors:  E L Peckham; G Lopez; E A Shamim; S Pirio Richardson; S Sanku; R Malkani; M Stacy; P Mahant; A Crawley; A Singleton; M Hallett
Journal:  Eur J Neurol       Date:  2011-03       Impact factor: 6.089

2.  Long-term follow-up of patients with frontalis sling operation in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy.

Authors:  Bettina Wabbels; Peter Roggenkämper
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-07-28       Impact factor: 3.117

3.  Animal models for investigating benign essential blepharospasm.

Authors:  Craig Evinger
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.